Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (351-360 of 578) with videos related to

Pageof 58
Sort By:
Journal of the National Cancer Institute|November 5, 2020
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerGiuseppe Floris, François Richard, Anne-Sophie Hamy, et al.
Menopause (New York, N.Y.)|October 1, 2010
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozoleBen Van Calster, Johan Van Ginderachter, Jos Vlasselaer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Gynecologic Oncology|December 11, 2012
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinomaDiego A Garcia-Dios, Diether Lambrechts, Lieve Coenegrachts, et al.
BMC Genomics|August 17, 2016
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancerMartin Svoboda, Anastasia Meshcheryakova, Georg Heinze, et al.
Histopathology|July 15, 2018
Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survivalSilvia Darb-Esfahani, Ivonne Kolaschinski, Fabian Trillsch, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Targeted Oncology|April 9, 2016
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 58

Showing results (351-360 of 578) with videos related to

Sort By:
Pageof 58
Journal of the National Cancer Institute|November 5, 2020
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerGiuseppe Floris, François Richard, Anne-Sophie Hamy, et al.
Menopause (New York, N.Y.)|October 1, 2010
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozoleBen Van Calster, Johan Van Ginderachter, Jos Vlasselaer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Gynecologic Oncology|December 11, 2012
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinomaDiego A Garcia-Dios, Diether Lambrechts, Lieve Coenegrachts, et al.
BMC Genomics|August 17, 2016
AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancerMartin Svoboda, Anastasia Meshcheryakova, Georg Heinze, et al.
Histopathology|July 15, 2018
Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survivalSilvia Darb-Esfahani, Ivonne Kolaschinski, Fabian Trillsch, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Targeted Oncology|April 9, 2016
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 58